Bio­phar­ma in­dus­try lob­by groups work­ing to keep the pipeline open for plen­ti­ful, low­er-cost drugs com­ing from Chi­na have awak­ened to the fact that they face...

The phar­ma in­dus­try and rare dis­ease ad­vo­cates voiced con­cerns about the trans­paren­cy and fair­ness of the Com­mis­sion­er's Na­tion­al Pri­or­i­ty Vouch­er pi­lot pro­gram.

The pro­gram faces...

The House Ap­pro­pri­a­tions Com­mit­tee told the FDA to re­form the way it signs off on new clin­i­cal tri­als, re­flect­ing a broad­er ef­fort to en­sure the...

In­novent Bi­o­log­ic­s' ADC can­di­date has passed a Phase 3 tri­al in ad­vanced stom­ach can­cer and is un­der pri­or­i­ty re­view in Chi­na, but de­tails of the...

Ot­su­ka Phar­ma­ceu­ti­cal re­port­ed new ev­i­dence on Thurs­day that it thinks will help sup­port a full ap­proval for its mon­o­clon­al an­ti­body Voyx­act in a chron­ic au­toim­mune...

Uli Stilz has been trot­ting the globe this year to talk about the fu­ture of biotech and bridge an in­creas­ing­ly in­ter­na­tion­al in­dus­try. He was in...